It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
In 1990, I began the first new human research with psychedelic, or hallucinogenic, drugs in the United States in over 20 years. These studies investigated the effects of N,N-dimethyltryptamine, or '___', an extremely short-acting and powerful psychedelic. During the project's five years, I administered approximately 400 doses of '___' to 60 human volunteers. This research took place at the University of New Mexico's School of Medicine in Albuquerque, where I was tenured Associate Professor of Psychiatry.
I was drawn to '___' because of its presence in all of our bodies. Perhaps excessive '___' production, coming from the mysterious pineal gland, was involved in naturally occurring "psychedelic" states. These might include birth, death and near-death, psychosis, and mystical experiences. Only later, while the study was well under way, did I also begin considering '___''s role in the "alien abduction" experience.
The '___' project was founded on cutting edge brain science, especially the psychopharmacology of serotonin. However, my own background powerfully affected how we prepared people for, and supervised, their drug sessions. One of these was a decades-long relationship with a Zen Buddhist training monastery.